openPR Logo
Press release

Retropharyngeal Abscess Market 2018 Expected To Surpass USD 5.9 Billion By The End Of 2023 | Top Key Players - AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others

01-07-2019 07:52 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Retropharyngeal Abscess Market

Retropharyngeal Abscess Market

MRFR is the Leading Brand in The Research Company who Recently Published Retropharyngeal Abscess Market Research Report which includes Study of growth, Regional Analysis, Top Industry Players Formation, Major Drivers, Upcoming Trends and Forecast to 2023

Market scenario:

A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4922

The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.

The causes of retropharyngeal abscess are trauma or injury, medical procedure, dental procedures, alcohol intake, diabetes, cancer, AIDS, weakened immune system or a chronic diseases such as tuberculosis and others. Other complications indicated are pneumonia, blood clots in the jugular vein, mediastinitis, osteomyelitis and others. If left untreated, retropharyngeal abscess infection can spread to other parts of the body resulting in septic shock and organ failure. In severe instances, a retropharyngeal abscess can lead to death. The most common bacteria involved are Streptococcus, Staphylococcus, and others. Other infections, such as HIV and tuberculosis can also cause the retropharyngeal abscess. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications. Retropharyngeal abscess also slightly more common in males than females.

The market drivers for global retropharyngeal abscess market, are rise in demand due to the growing younger and susceptible population, increasing screening, urgency of the retropharyngeal abscess treatment, and rise in risk factors. The rise in cases of retropharyngeal abscess due to increase in Methicillin-resistant Staphylococcus aureus (MRSA) infections also stimulates the market. The market restraints are complications such as risk of bleeding, infections, pain, especially during surgery, high cost of retropharyngeal abscess treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.

Key Players in the Global Retropharyngeal abscess Market

• Merck KGaA,
• Johnson & Johnson,
• AstraZeneca plc,
• Sanofi S.A.,
• Pfizer,
• Mylan N.V,
• Novartis AG,
• Teva pharmaceutical company,
• GlaxoSmithKline plc.

Segments

The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.

A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.

Browse Complete 85 Pages Premium Research Report Enabled with 66 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/retropharyngeal-abscess-market-4922

Detailed Table of Contents:

Table Of Contents

1 Introduction

1.1 Definition

1.2 Scope Of Study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure:

2 Research Methodology

2.1 Research Process:

2.2 Primary Research

2.3 Secondary Research:

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porters Five Forces Model

4.2 Bargaining Power Of Suppliers

4.3 Bargaining Power Of Buyers

4.4 Threat Of New Entrants

4.5 Threat Of Substitutes

4.6 Intensity Of Rivalry

...Continued!

Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/4922

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retropharyngeal Abscess Market 2018 Expected To Surpass USD 5.9 Billion By The End Of 2023 | Top Key Players - AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others here

News-ID: 1473749 • Views:

More Releases from Market Research Future

Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR by 2032
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview: The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical
Laboratory Equipment Market Projected to Reach USD 102.11 Billion with 7.66% CAGR by 2032
Laboratory Equipment Market Projected to Reach USD 102.11 Billion with 7.66% CAG …
Market Overview: The Laboratory Equipment Market is estimated to be valued at USD 49.6 billion in 2024 and is projected to reach USD 78.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031. The market growth is primarily driven by the rising demand for advanced research tools in pharmaceuticals, biotechnology, clinical diagnostics, and academic institutes. Increasing investment in R&D activities, coupled with technological
Medical Second Opinion Market Set to Grow to USD 21.36 Billion at a 14.30% CAGR by 2034
Medical Second Opinion Market Set to Grow to USD 21.36 Billion at a 14.30% CAGR …
Market Overview: The Medical Second Opinion Market is estimated to grow significantly from 2024 to 2031, driven by the rising need for accurate diagnosis, treatment validation, and better patient care. A second opinion helps patients make more informed healthcare decisions, particularly in cases of complex surgeries, rare diseases, or chronic illnesses. With increasing awareness among patients about medical errors and the importance of exploring alternative treatments, the demand for medical second
Penicillin Drug Market Forecasted to Surpass USD 14.36 Billion at a 3.64% CAGR by 2034
Penicillin Drug Market Forecasted to Surpass USD 14.36 Billion at a 3.64% CAGR b …
Market Overview: The Penicillin Drug Market is estimated to be valued significantly in 2024 and is projected to grow steadily, reaching a substantial valuation by 2031. This growth is driven by the continued reliance on penicillin as a frontline antibiotic and its wide therapeutic applications in bacterial infection management. Penicillin remains one of the most widely prescribed antibiotics globally, with demand sustained by rising bacterial infection prevalence, increasing healthcare expenditure, and

All 5 Releases


More Releases for Retropharyngeal

Retropharyngeal Abscess Treatment Market Analysis and Future Prospects for 2030
The world of the retropharyngeal abscess treatment market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing
Retropharyngeal Abscess Market Growth, Development Factors, Applications, and Fu …
International Retropharyngeal Abscess Industry Report focuses on Market Influence Factors, Growth Drivers, Restraints, Trends and Opportunities so that Market Players can face any challenges and take advantage of Lucrative Prospects available in the Global Retropharyngeal Abscess market. The report provides study at global and regional level to provide comprehensive value market analysis for the years. The Retropharyngeal Abscess Market research report is a wide-ranging study of current trends, market growth drivers,
Retropharyngeal Abscess Market 2023 Industry Analysis, Size, Share, Growth, Tren …
Worldwide Market Reports published a "Retropharyngeal Abscess Market Business Growth Forecast 2023-2030" report that sheds light on the key opportunities attributing to the growth of the market. This Insight Report offers a thorough study of the global Retropharyngeal Abscess market and identifies significant trends in product/services segmentation, company formation, revenue, market share, recent advancements, and M&A activity. With a focus on Retropharyngeal Abscess portfolios and capabilities, market entry strategies, market
Retropharyngeal Abscess Market With Leading Players like Merck KGaA, Johnson & J …
An off-the-shelf report on Retropharyngeal Abscess Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as type/components/ application/industry verticals/ end-users are analyzed with robust research methodology which includes three step process starting with extensive secondary research to gather data from company profiles, global/regional associations, trade journals,
Retropharyngeal Abscess Treatment Market Potential Growth, Share, Demand And Ana …
Complete study of the global Retropharyngeal Abscess Treatment market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Retropharyngeal Abscess Treatment industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They
Retropharyngeal Abscess Market to Witness a Pronounce Growth During 2020 To 2025
California, March 26, 2020: The scope of the report includes a detailed study of global and regional markets on Retropharyngeal Abscess Market with the reasons given for variations in the growth of the industry in certain regions. The Global Retropharyngeal Abscess Market is expected to exceed more than US$ 6.0 Billion by 2024 at a CAGR 4.5% in the given forecast period. Browse Full Report: https://www.marketresearchengine.com/retropharyngeal-abscess-market The Global Retropharyngeal Abscess Market is